Maria Liguori

Dr. Maria Liguori

Consiglio Nazionale delle Ricerche (CNR), Institute of Biomedical Technologie
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
RRR. H.S.R. Roxburgh
R. H.S.R. Roxburgh
SSS. R. Seaman
S. R. Seaman
TMT. Masterman
T. Masterman
AHA. E. Hensiek
A. E. Hensiek
SSS. J. Sawcer
S. J. Sawcer
DCD.A.S. Compston
D.A.S. Compston
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.

24 December 2007 in Brain
Verified
Journal Article
Open access
PDF file
PAPatrizia Amati-Bonneau
Patrizia Amati-Bonneau
MVMaria Lucia Valentino
Maria Lucia Valentino
PRPascal Reynier
Pascal Reynier
M. ESTHER GALLARDO PEREZM. ESTHER GALLARDO PEREZ
M. ESTHER GALLARDO PEREZ
BBBelén Bornstein
Belén Bornstein
Valerio CarelliValerio Carelli
Valerio Carelli
Mutations in OPA1, a dynamin-related GTPase involved in mitochondrial fusion, cristae organization and control of apoptosis, have been linked to non-syndromic optic neuropathy transmitted as an autosomal-dominant trait (DOA). We here report on eight patients from six independent families showing that mutations in the OPA1 gene can also be responsible for a syndromic form of DOA associated with sensorineural deafness, ataxia, axonal sensory-motor polyneuropathy, chronic progressive external ophthalmoplegia and mitochondrial myopathy with cytochrome c oxidase negative and Ragged Red Fibres. Most remarkably, we demonstrate that these patients all harboured multiple deletions of mitochondrial DNA (mtDNA) in their skeletal muscle, thus revealing an unrecognized role of the OPA1 protein in mtDNA stability. The five OPA1 mutations associated with these DOA ‘plus’ phenotypes were all mis-sense point mutations affecting highly conserved amino acid positions and the nuclear genes previously known to induce mtDNA multiple deletions such as POLG1, PEO1 (Twinkle) and SLC25A4 (ANT1) were ruled out. Our results show that certain OPA1 mutations exert a dominant negative effect responsible for multi-systemic disease, closely related to classical mitochondrial cytopathies, by a mechanism involving mtDNA instability.

24 December 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
ISIsabella Laura Simone
Isabella Laura Simone
DCD. Carrara
D. Carrara
CTCarla Tortorella
Carla Tortorella
MLMaria Liguori
Maria Liguori
VLV. Lepore
V. Lepore
PLP. Livrea
P. Livrea
Objectives: To establish the prognostic role of clinical and demographic factors in a hospital-based cohort of MS patients categorized by age at clinical onset and clinical course. Methods: Eighty-three patients with MS had a clinical onset of the disease in childhood (age <16 years; early-onset MS [EOMS]) and 710 in adult age (between 16 and 65 years; adult-onset MS [AOMS]). Patients were followed for a mean period of observation of 5 years. Univariate and multivariate analyses of clinical and demographic predictors for rapid progression and disability were performed using a stepwise Cox regression model with time-dependent covariates. Results: In EOMS, the Expanded Disability Status Scale (EDSS) evaluated at last clinical examination was lower than in AOMS, despite a longer disease duration. The probability to reach growth disability and progression was significantly lower in EOMS than in AOMS. Median times to reach EDSS score of 4 and secondary progression were longer in EOMS than in AOMS, but the age at both endpoints was significantly lower in EOMS. In EOMS and AOMS, an irreversible disability was related to a secondary progressive course, a sphincteric system involvement at onset, and an older age at onset (in EOMS only for the group >14 years); in AOMS, other unfavorable factors were a pyramidal involvement at onset and a high relapse frequency in the first 2 years. The risk of entering secondary progression was significantly influenced by a high number of relapses in EOMS and by a higher age at onset and a short interattack interval in AOMS. Conclusion: A slower rate of progression of disease characterized EOMS patients, suggesting more plasticity to recover in developing CNS, but the early clinical manifestation cannot be considered a positive prognostic factor.

1 February 1997 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
AGA. Ghezzi
A. Ghezzi
VDV. Deplano
V. Deplano
JFJ. Faroni
J. Faroni
MGMg Grasso
Mg Grasso
MLMaria Liguori
Maria Liguori
MZM. Zaffaroni
M. Zaffaroni
From the retrospective study of 3375 patients affected by clinically definite or probable multiple sclerosis (MS), 149 patients were collected with onset of the disease before the age of 16 years (4.4%). Female/male ratio was higher than that of the adult onset MS (AOMS) population (2.2 vs 1.6) particularly at ages of onset after 12 years (3.0, P=0.007 vs AOMS). Among initial symptoms, those suggesting brainstem dysfunction (25%) were more frequent compared to other systems and compared to AOMs symptoms; motor and sensory disturbances were slightly less frequent (respectively 17.5% and 18.3%). Optic neuritis appeared in 16.5% of cases with onset in childhood and in 16.2% of cases with AOMS, cerebellar disturbances respectively in 9.1 % and 7.7%. The first interattack interval and the clinical course of early onset MS did not differ significantly from AOMS. In early onset MS patients with disease duration < 8 years, cases with EDSS > 6 were slightly more frequent than in the AOMS group (P=0.04). The frequency of cases for different levels of disability was similar for disease duration > 8 years.

19 March 2002 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MTMaria Trojano
Maria Trojano
MLMaria Liguori
Maria Liguori
GZGiovanni Bosco Zimatore
Giovanni Bosco Zimatore
RBRoberto Bugarini
Roberto Bugarini
CACarlo Avolio
Carlo Avolio
PLPaolo Livrea
Paolo Livrea

1 October 2004 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GSGiovanni Savettieri
Giovanni Savettieri
DMDemetrio Messina
Demetrio Messina
VAVirginia Andreoli
Virginia Andreoli
SBSimona Bonavita
Simona Bonavita
CCCarlo Caltagirone
Carlo Caltagirone
AQAldo Quattrone
Aldo Quattrone